Antibody responses in primary HIV-1 infection

Current Opinion in HIV and AIDS

Volumn 3, Issue 1, 2008, Pages 45-51

  Frost, Simon D W ^a,e   Trkola, Alexandra ^b   Günthard, Huldrych F ^b   Richman, Douglas D ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; Humoral responses; Neutralizing antibody

Indexed keywords

ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ANTIBODY RESPONSE; B LYMPHOCYTE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GLYCOSYLATION; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOASSAY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS TYPING;

EID: 40349088569     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f310ae     Document Type: Review

References (86)

1. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001; 77:195-262.
2. Moore JP, Cao Y, Ho DD, Koup RA. Development of the antigp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68:5142-5155.
3. Bélec L, Dupré T, Prazuck T, et al. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 1995; 172:691-697.
4. Binley JM, Klasse PJ, Cao Y, et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997; 71:2799-2809.
5. Huber M, Fischer M, Misselwitz B, et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006; 3:e441. This paper presents a novel real-time PCR-based assay to quantify virus lysis by complement, which is used to compare complement lysis in 25 individuals with acute HIV-1 infection and 31 with chronic HIV-1 infection. Antibody-mediated complement virion lysis developed rapidly, and was effective early in the course of infection, and was independent of neutralizing antibody activity.
6. Parren PW, Burton DR, Sattentau QJ. HIV-1 antibody: debris or virion? Nat Med 1997; 3:366-367.
7. Fouts TR, Binley JM, Trkola A, et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997; 71:2779-2785.
8. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 2005; 102:14943-14948.
9. Dhillon AK, Donners H, Pantophlet R, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007; 81:6548-6562. This study characterized the neutralizing antibody specificities present in the sera of three asymptomatic individuals, two infected with subtype B HIV-1 and one infected with subtype A HIV-1, who exhibit broad neutralization. Antibodies directed against linear epitopes in the V3 region of gp120 and those directed against conserved regions of gp41 were not responsible for the broad neutralizing activity observed. The authors concluded that the most likely epitope recognized by the monomeric gp120 binding neutralizing fraction is the CD4 binding site, although other epitopes, such as the glycan shield, cannot be excluded.
10. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034. This study mapped the neutralizing specificities of two broadly reactive sera to the primary receptor CD4-binding region of HIV-1 gp120, and demonstrated that novel antibodies to the CD4-binding site are elicited in some HIV-1-infected individuals.
11. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-112.
12. Moog C, Fleury HJ, Pellegrin I, et al. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71:3734-3741.
13. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
14. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
15. Geffin R, Hutto C, Andrew C, Scott GB. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 2003; 310:207-215.
16. Deeks SG, Schweighardt B, Wrin T, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006; 80:6155-6164. This study demonstrated that although autologous and heterologous neutralizing antibody responses were lower in individuals with acute HIV-1 infection compared with those with chronic HIV-1 infection, the rate of escape from neutralizing antibodies was more rapid in those with acute infection. The authors conclude that, although HIV continuously drives the production of neutralizing antibodies, there may be limits to the capacity of the virus to evolve continuously in response to these antibodies. An equally parsimonious explanation, however, is that antibody responses weaken during infection, resulting in a lower selection pressure for the virus to escape.
17. Gauduin MC, Parren PW, Weir R, et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3:1389-1393.
18. Poignard P, Sabbe R, Picchio GR, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431-438.
19. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5:204-210.
20. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
21. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
22. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001; 75:7470-7480.
23. Montefiori DC, Hill TS, Vo HT, et al. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 2001; 75:10200-10207.
24. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-8347.
25. Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol 2001; 8:350-358.
26. Haigwood NL, Montefiori DC, Sutton WF, et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004; 78:5983-5995.
27. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
28. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262:5-25. This is a recent review of neutralizing and nonneutralizing mechanisms of humoral responses to HIV-1.
29. Hessel AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104. This study reported a dramatic decrease in the ability of a broadly neutralizing antibody to protect macaques against SHIV challenge when Fc receptor and complement-binding activities were engineered out of the antibody. No loss of antibody protective activity was associated with the elimination of complement binding alone. These results suggest that the interaction of Fc-receptor-bearing effector cells with antibody-complexed infected cells is important in reducing virus yield from infected cells.
30. Martínez-Maza O, Crabb E, Mitsuyasu RT, et al. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 1987; 138:3720-3724.
31. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992; 89:561-566.
32. Kouri YH, Basch RS, Karpatkin S. B-cell subsets and platelet counts in HIV-1 seropositive subjects. Lancet 1992; 339:1445-1446.
33. Indraccolo S, Mion M, Zamarchi R, et al. B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5- B cell subsets. J Clin Immunol 1993; 13:381-388.
34. Malaspina A, Moir S, Ho J, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A 2006; 103:2262-2267. This study identified a population of immature/transitional B cells identified by the expression of CD10 that is overly represented in the peripheral blood of individuals with advancing HIV disease. As levels of CD10 expression on B cells were directly correlated with serum levels of IL-7, the authors conclude that B cell dysfunction in advanced HIV disease that may be linked to IL-7-dependent homeostatic events.
35. De Milito A, Mörch C, Sönnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001; 15:957-964.
36. Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001; 98:10362-10367.
37. Nagase H, Agematsu K, Kitano K, et al. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol 2001; 100:250-259.
38. Terpstra FG, Al BJ, Roos MT, et al. Longitudinal study of leukocyte functions in homosexual men seroconverted for HIV: rapid and persistent loss of B cell function after HIV infection. Eur J Immunol 1989; 19:667-673.
39. Conge AM, Tarte K, Reynes J, et al. Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS 1998; 12:1437-1449.
40. Malaspina A, Moir S, Kottilil S, et al. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003; 170:5965-5972.
41. Moir S, Ogwaro KM, Malaspina A, et al. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A 2003; 100:6057-6062.
42. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A 1991; 88:9838-9842.
43. Frost SD, McLean AR. Germinal centre destruction as a major pathway of HIV pathogenesis. J Acquir Immune Defic Syndr 1994; 7:236-244.
44. Qiao X, He B, Chiu A, et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7:302-310. This study showed that that negative factor (Nef) protein penetrates B cells both in vivo and in vitro, and suppresses immunoglobulin class-switch DNA recombination.
45. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005; 19:1947-1955.
46. Titanji K, Milito AD, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108:1580-1587. This study evaluated the frequency of memory B cells, plasma IgG, plasma levels of antibodies to measles and Streptococcus pneumoniae, and enumerated measles-specific antibody-secreting cells in patients with primary, chronic, and long-term nonprogressive HIV-1 infection. Patients with primary and chronic infection had severe defects in serologic memory, while long-term nonprogressors had memory B-cell frequency and levels of antigen-specific antibodies comparable with controls. Antiretroviral therapy did not restore serologic memory in primary or in chronic infection.
47. Tremblay M, Wainberg MA. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis 1990; 162:735-737.
48. Montefiori DC, Zhou IY, Barnes B, et al. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology 1991; 182:635-643.
49. Arendrup M, Nielsen C, Hansen JE, et al. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992; 5:303-307.
50. Tsang ML, Evans LA, McQueen P, et al. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994; 170:1141-1147.
51. Wrin T, Crawford L, Sawyer L, et al. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7:211-219.
52. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997; 176:924-932.
53. Ruppach H, Nara P, Raudonat I, et al. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. J Virol 2000; 74:5403-5411.
54. Skrabal K, Saragosti S, Labernardiè re JL, et al. Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J Virol 2005; 79:11848-11857.
55. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002; 2:28-36.
56. Haraguchi Y, Sasaki A. Evolutionary pattern of intra-host pathogen antigenic drift: effect of cross-reactivity in immune response. Philos Trans R Soc Lond B Biol Sci 1997; 352:11-20.
57. Sasaki A, Haraguchi Y. Antigenic drift of viruses within a host: a finite site model with demographic stochasticity. J Mol Evol 2000; 51:245-255.
58. Frost SDW, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005; 102:18514-18519.
59. Draenert R, Allen TM, Liu Y, et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med 2006; 203:529-539. This unique study examined adaptive HIV-specific cellular and humoral immune responses and viral evolution in two adult monozygotic twins simultaneously infected with the same virus, and their sibling, who was infected by one of the twins. There was considerable concordance of adaptive cellular and humoral immune responses and HIV evolution in the twins, suggesting constraints on mutational pathways to HIV immune escape.
60. Binley JM, Trkola A, Ketas T, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:945-949.
61. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-873.
62. Bailey JR, Lassen KG, Yang HC, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006; 80:4758-4770. This study analyzed viral genetic variation and autologous neutralization in HAART treated patients, elite suppressors, and untreated HIV-1-infected patients with progressive disease. The degree of env diversity, the number of N-linked glycosylation sites, and the lengths of variable loops were all lower in elite suppressors than in HAART-treated and untreated viremic patients. Both elite suppressors and HAART treated patients had lower titers of neutralizing antibodies against HIV-1 laboratory strains than those of untreated viremic patients. Titers of neutralizing antibodies against autologous, contemporaneous plasma viruses were similarly low in chronic progressors, elite suppressors, and HAART-treated patients.
63. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12:585-592.
64. Trkola A, Kuster H, Leemann C, et al. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004; 104:1784-1792.
65. Wahlberg J, Albert J, Lundeberg J, et al. Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. AIDS Res Hum Retroviruses 1991; 7:983-990.
66. Arendrup M, Sönnerborg A, Svennerholm B, et al. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol 1993; 74 (Pt 5):855-863.
67. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005; 21:171-189.
68. Vancott TC, Polonis VR, Loomis LD, et al. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995; 11:1379-1391.
69. Spenlehauer C, Saragosti S, Fleury HJ, et al. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J Virol 1998; 72:9855-9864.
70. Krachmarov CP, Kayman SC, Honnen WJ, et al. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1737-1748.
71. Gorny MK, Revesz K, Williams C, et al. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 2004; 78:2394-2404.
72. Yamaguchi-Kabata Y, Gojobori T. Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes. J Virol 2000; 74:4335-4350.
73. Joos B, Fischer M, Schweizer A, et al. Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regions. J Infect Dis 2007; 196:313-320. By analyzing genetic sequences of HIV-1 env, the authors demonstrate that positively selected amino acids mapped almost exclusively to externally accessible residues on the gp120 crystal structure, consistent with the possible role of neutralizing antibodies driving the evolution of the viral envelope.
74. Joos B, Trkola A, Fischer M, et al. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 2005; 79:9026-9037.
75. Trkola A, Kuster H, Leemann C, et al. Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J Virol 2003; 77:13146-13155.
76. Poon AFY, Lewis FI, Pond SLK, Frost SDW. Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope. PLoS Comput Biol 2007; 3:e11. The authors identify specific interactions between potential N-linked glycosylation sites in the HIV-1 envelope, by applying two statistical models to HIV-1 sequence data. Mapping these interactions onto a structural model of HIV-1 gp120 reveals that negative (exclusive) interactions occur significantly more often between colocalized glycans, while positive (inclusive) interactions are restricted to more distant glycans. The authors conclude that the adaptive repertoire of alternative configurations in the HIV-1 glycan shield is limited by functional interactions between the N-linked glycans.
77. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80:9586-9598. The authors investigate the evolution of the V1-V2 region of HIV-1 envelope in nine women infected with subtype A HIV-1. HIV-1 sequences isolated during chronic infection had significantly longer V1-V2 loops, with a significantly higher number of potential N-linked glycosylation sites, than the sequences isolated early in infection. Compared with the parent virus, the introduction of a subject's early-infection V1-V2 envelope variable loops into a common subtype A backbone rendered the chimeric envelope more sensitive to that subject's plasma samples, but only to plasma samples collected more than 6 months after the sequences were isolated. Neutralization was not detected with the same plasma when the early-infection V1-V2 sequences were replaced with chronic-infection V1-V2 sequences, suggesting that changes in V1-V2 contribute to antibody escape.
78. Bongertz V, Costa CI, Santos VG, et al. Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. Hospital Evandro Chagas AIDS Clinical Research Group. AIDS 1997; 11:969-975.
79. Mehandru S, Wrin T, Galovich J, et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 2004; 78:14039-14042.
80. Rusert P, Kuster H, Joos B, et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005; 79:8454-8469.
81. Dacheux L, Moreau A, Ataman-Onal Y, et al. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol 2004; 78:12625-12637.
82. Li B, Decker JM, Johnson RW, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006; 80:5211-5218. This study evaluated neutralizing antibody responses in six subtype B infected and 11 subtype C infected subjects over a mean evaluation period of 25 months using a pseudovirus reporter gene assay. Autologous neutralizing antibody titers were significantly higher in subtype C infected individuals than in subtype B infected individuals; however, despite the potency of the autologous subtype C neutralizing antibody response, plasma from these individuals showed little ability to neutralize heterologous viruses.
83. Gray ES, Moore PL, Choge IA, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81:6187-6196. This study investigated autologous and heterologous neutralization responses of 14 HIV-1 subtype C-infected individuals, using envelope clones obtained within the first 2 months postinfection. Potent but relatively strain-specific neutralizing antibodies developed within 3-12 months of HIV-1 infection. The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region. Although antimembrane-proximal external region (MPER) antibodies were detected in 4 out of 14 individuals and antibodies to CD4-induced (CD4i) epitopes developed in 12 participants, neither anti-MPER nor anti-CD4i antibody specificity conferred neutralization breadth.
84. Smith DM, Strain MC, Frost SDW, et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006; 355:1-5. Three individuals identified with HIV superinfection had less cross-protective and autologous neutralizing antibody response than their nonsuperinfected case-controls, suggesting that neutralizing antibodies may play a role in protection from superinfection.
85. Rybarczyk BJ, Montefiori D, Johnson PR, et al. Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol 2004; 78:3561-3571.
86. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10:871-875.